190 related articles for article (PubMed ID: 20931299)
1. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
[TBL] [Abstract][Full Text] [Related]
2. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
[TBL] [Abstract][Full Text] [Related]
4. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
[TBL] [Abstract][Full Text] [Related]
5. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Candelaria M; Cetina L; Pérez-Cárdenas E; de la Cruz-Hernández E; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Chanona J; Arias D; Dueñas-González A
Eur J Gynaecol Oncol; 2010; 31(4):386-91. PubMed ID: 20882878
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
Espinoza-Zamora JR; Labardini-Méndez J; Sosa-Espinoza A; López-González C; Vieyra-García M; Candelaria M; Lozano-Zavaleta V; Toledano-Cuevas DV; Zapata-Canto N; Cervera E; Dueñas-González A
Expert Opin Investig Drugs; 2017 Apr; 26(4):481-487. PubMed ID: 28277033
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Cervera E; Candelaria M; López-Navarro O; Labardini J; Gonzalez-Fierro A; Taja-Chayeb L; Cortes J; Gordillo-Bastidas D; Dueñas-González A
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):207-12. PubMed ID: 22420986
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
[TBL] [Abstract][Full Text] [Related]
12. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
[TBL] [Abstract][Full Text] [Related]
13. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.
Gupta S; Maheshwari A; Parab P; Mahantshetty U; Hawaldar R; Sastri Chopra S; Kerkar R; Engineer R; Tongaonkar H; Ghosh J; Gulia S; Kumar N; Shylasree TS; Gawade R; Kembhavi Y; Gaikar M; Menon S; Thakur M; Shrivastava S; Badwe R
J Clin Oncol; 2018 Jun; 36(16):1548-1555. PubMed ID: 29432076
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies.
Kumar L; Grover R; Pokharel YH; Chander S; Kumar S; Singh R; Rath GK; Kochupillai V
Aust N Z J Med; 1998 Jun; 28(3):387-90. PubMed ID: 9673754
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.
Rose PG; Ali S; Watkins E; Thigpen JT; Deppe G; Clarke-Pearson DL; Insalaco S;
J Clin Oncol; 2007 Jul; 25(19):2804-10. PubMed ID: 17502627
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Sundfør K; Tropé CG; Högberg T; Onsrud M; Koern J; Simonsen E; Bertelsen K; Westberg R
Cancer; 1996 Jun; 77(11):2371-8. PubMed ID: 8635109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
